Axsome Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05, which is in the Phase III clinical trial for the treatment resistant depression; Phase II/III clinical trials in agitation associated with Alzheimer's disease; and Phase II clinical trial for the treatment of smoking cessation, as well as for major depressive disorder.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone212-332-3241
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees29
Next Earnings Date11/8/2019 (Estimated)
OptionableOptionable
Axsome Therapeutics (NASDAQ:AXSM) Frequently Asked Questions
What is Axsome Therapeutics' stock symbol?
Axsome Therapeutics trades on the NASDAQ under the ticker symbol "AXSM."
How were Axsome Therapeutics' earnings last quarter?
Axsome Therapeutics Inc (NASDAQ:AXSM) posted its earnings results on Thursday, August, 8th. The company reported ($0.41) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.31) by $0.10. View Axsome Therapeutics' Earnings History.
When is Axsome Therapeutics' next earnings date?
What price target have analysts set for AXSM?
9 Wall Street analysts have issued twelve-month price targets for Axsome Therapeutics' shares. Their forecasts range from $25.00 to $48.00. On average, they anticipate Axsome Therapeutics' share price to reach $35.13 in the next year. This suggests a possible upside of 66.9% from the stock's current price. View Analyst Price Targets for Axsome Therapeutics.
What is the consensus analysts' recommendation for Axsome Therapeutics?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axsome Therapeutics in the last year. There are currently 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Axsome Therapeutics.
Has Axsome Therapeutics been receiving favorable news coverage?
News coverage about AXSM stock has trended somewhat negative recently, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Axsome Therapeutics earned a media sentiment score of -1.5 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Axsome Therapeutics.
Who are some of Axsome Therapeutics' key competitors?
Some companies that are related to Axsome Therapeutics include Global Blood Therapeutics (GBT), Alkermes (ALKS), Emergent Biosolutions (EBS), Genmab A/S (GMAB), Myokardia (MYOK), Ultragenyx Pharmaceutical (RARE), HUTCHISON CHINA/S (HCM), Arena Pharmaceuticals (ARNA), Biohaven Pharmaceutical (BHVN), PTC Therapeutics (PTCT), Ra Pharmaceuticals (RARX), BridgeBio Pharma (BBIO), Intercept Pharmaceuticals (ICPT), Amicus Therapeutics (FOLD) and Xencor (XNCR).
What other stocks do shareholders of Axsome Therapeutics own?
Who are Axsome Therapeutics' key executives?
Axsome Therapeutics' management team includes the folowing people:
- Dr. Herriot Tabuteau M.D., Founder, Chairman, CEO & Pres (Age 51)
- Mr. Nick Pizzie, CFO & Principal Accounting Officer (Age 44)
- Mr. Mark Jacobson, Sr. VP of Operations & Sec. (Age 36)
- Dr. Cedric O'Gorman M.D., MBA, Sr. VP of Clinical Devel. & Medical Affairs (Age 44)
- Joseph Debrah-Afful, Director of Fin.
When did Axsome Therapeutics IPO?
(AXSM) raised $52 million in an IPO on Thursday, November 19th 2015. The company issued 4,300,000 shares at a price of $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. served as the underwriters for the IPO and Brean Capital was co-manager.
Who are Axsome Therapeutics' major shareholders?
Axsome Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Zurcher Kantonalbank Zurich Cantonalbank (0.01%). Company insiders that own Axsome Therapeutics stock include Mark Coleman, Mark E Saad and Nick Pizzie. View Institutional Ownership Trends for Axsome Therapeutics.
Which major investors are selling Axsome Therapeutics stock?
How do I buy shares of Axsome Therapeutics?
Shares of AXSM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Axsome Therapeutics' stock price today?
One share of AXSM stock can currently be purchased for approximately $21.04.
How big of a company is Axsome Therapeutics?
Axsome Therapeutics has a market capitalization of $724.18 million. The company earns $-30,970,000.00 in net income (profit) each year or ($1.15) on an earnings per share basis. Axsome Therapeutics employs 29 workers across the globe.View Additional Information About Axsome Therapeutics.
What is Axsome Therapeutics' official website?
How can I contact Axsome Therapeutics?
Axsome Therapeutics' mailing address is 25 BROADWAY 9TH FLOOR, NEW YORK NY, 10004. The company can be reached via phone at 212-332-3241.
MarketBeat Community Rating for Axsome Therapeutics (NASDAQ AXSM)
MarketBeat's community ratings are surveys of what our community members think about Axsome Therapeutics and other stocks. Vote "Outperform" if you believe AXSM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AXSM will underperform the S&P 500 over the long term. You may vote once every thirty days.
